UCB’s Cimzia bags EU label extension
Drug is first biologic in Europe to be approved with a dose reduction label for axSpA patients
Read More
Tag: Cimzia
NICE final guidance published for Cimzia
For adults who have failed to respond to, or are unsuitable for, other systemic therapies.
Read More
Aimovig leads latest SMC decisions
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read More
FDA label expansion for UCB’s Cimzia
The FDA has approved the drug for a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis.
Read More
NICE backs Cimzia for psoriasis, but rejects Ilumetri
Cost watchdog the National Institute for Health and Care Excellence has backed NHS funding for UCB’s Cimzia as a treatment for psoriasis, but is not recommending Almirall’s Ilumetri.
Read More
EU green light for Cimzia to treat psoriasis
The European Medicines Agency has approved a label extension for UCB’s Cimzia allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Read More
AZ’ lung cancer drug Tagrisso backed for first-line use
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
Read More
NICE nod for psoriatic arthritis drugs Cimzia and Cosentyx
Cost regulators for the NHS in England and Wales are recommending UCB’s Cimzia and Novartis’ Cosentyx as treatment options for adults with active psoriatic arthritis.
Read More
UCB, Dermira plan psoriasis filing for Cimzia in Q3
UCB and Dermira are expecting to file anti-inflammatory Cimzia for psoriasis in the third quarter of this year, after the drug’s strong performance in a late-stage trial involving patients with severe chronic plaque forms of the skin disease.
Read More
NICE backs use of UCB’s Cimzia, Novartis’ Cosentyx for psoriatic arthritis
Cost regulators for the NHS in England and Wales are backing UCB’s Cimzia and Novartis’ Cosentyx as treatment options for adults with active psoriatic arthritis.
Read More
NICE nods for Tagrisso, Cimzia and Zepatier
Cost regulators for treatments used by the NHS in England and Wales have published three sets of final guidances giving routine access to new options for lung cancer, rheumatoid arthritis and hepatitis C, and one rejecting a new therapy for melanoma.
Read More
UCB launches new Cimzia self-injector in the UK
UCB says it has launched in the UK a new pre-filled self-injecting device for its anti-inflammatory drug Cimzia that was designed in collaboration with patients.
Read More
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
